| Literature DB >> 24778867 |
Ching-Hsi Hsiao1, Lung-Kun Yeh1, Hung-Chi Chen1, Hsin-Chiung Lin1, Phil Y F Chen1, David H K Ma1, Hsin-Yuan Tan1.
Abstract
Purpose. Alternaria spp. are an uncommon cause of mycotic keratitis. Previous studies on Alternaria keratitis have generally been limited to case reports. We examined the clinical characteristics of Alternaria keratitis in this study. Methods. The characteristics and outcomes of 7 patients with culture-proven Alternaria keratitis treated in our hospital were compared with 25 previously reported cases. Results. The risk factors for Alternaria keratitis were trauma in 5 patients and soft contact lenses in 1 patient. Six patients with early diagnosis (<2 weeks) were cured with medical antimicrobial treatment; a patch graft was required in 1 patient with perforation. When incorporated with previous reports on Alternaria keratitis (n = 32), 14 (44%) infections followed trauma, 10 (31%) were associated with preexisting corneal disease or previous ocular surgery, and 5 (16%) occurred in soft contact lens wearers. Successful medical treatment was achieved in 23 (72%) patients, including 10 out of 21 eyes (48%) treated with natamycin and/or amphotericin B. Therapeutic penetrating keratoplasty was performed in 9 (28%) cases. Conclusions. Alternaria keratitis is generally associated with specific risk factors and responds to medical treatment when early diagnosis is performed and prompt antifungal treatment is initiated.Entities:
Year: 2014 PMID: 24778867 PMCID: PMC3981128 DOI: 10.1155/2014/536985
Source DB: PubMed Journal: J Ophthalmol ISSN: 2090-004X Impact factor: 1.909
Clinical data of patients with Alternaria keratitis.
| Patient | Risk factors | Location and size | Medical treatment | Surgery | Initial VA | Final VA | F/U (months) | Others |
|---|---|---|---|---|---|---|---|---|
| 1 | Trauma | C, 4 × 3 mm | Natamycin + Amphotericin B | CF | 20/200 | 2 | ||
| 2 | Trauma | C, 2 × 2 mm | Amphotericin B | 20/200 | 20/100 | 10 | ||
| 3 | Unknown, DM | C, 4 × 4.4 mm | Natamycin + amikacin + ciprofloxacin | Superficial keratectomy | 20/200 | 20/70 | 16 | (i) Cataract operation 1 month ago |
| 4 | Trauma | C, 3.6 × 3 mm | Natamycin | Superficial keratectomy, patch graft | CF | 20/200 | 15 | PKP + ECCE + IOL 5 |
| 5 | Trauma | C, 3 × 4 mm | Natamycin | CF | 20/100 | 29 | ||
| 6 | Trauma | C, 2 × 2 mm | Natamycin + amphotericin B | 20/400 | 20/100 | 4 | ||
| 7 | SCL | P, 1 × 1 mm | Cefazolin + amikacin | 20/25 | 20/20 | 2 |
DM: diabetes mellitus, SCL: soft contact lens, C: central, P: peripheral, CF: counting fingers, F/U: follow-up, PKP: penetrating keratoplasty, ECCE: extracapsular cataract extraction, and IOL: intraocular lens.
Figure 1Alternaria keratitis presenting as a central corneal infiltrate with feathery margin. (a) Patient 3, coinfected with Mycobacterium chelonae. (b) Patient 5.
Previously reported cases of Alternaria keratitis.
| Reference, report year | Age/sex | Risk factor | Antifungal medication | Surgery | Others |
|---|---|---|---|---|---|
| Azar et al., 1975 [ | 53/M | HSV keratitis | Topical natamycin | PKP | |
|
Ando and Takatori, 1987 [ | 53/F | PKP | Topical thimerosal, pimaricin, flucytosine | ||
| Chang et al., 1994 [ | 55/M | Trauma | Topical miconazole, fluconazole | PKP | Combined endophthalmitis |
|
Arrese et al., 1996 [ | 46/M | Systemic steroids | Itraconazole | PKP | |
| Daniel et al., 1997 [ | 45/M | Trauma | Topical ketoconazole | ||
| Koc et al., 1997 [ | 82/M | ECCE | Topical fluconazole | ||
| Ferrer et al., 2002 [ | 50/M | Trauma | Topical amphotericin B, fluconazole | PKP | |
| Zahra et al., 2002 [ | 55/M | Trauma, DM | Topical amphotericin B | ||
| Ferrer et al., 2003 [ | 66/M | Trauma | Topical amphotericin B, fluconazole | Combined with endophthalmitis | |
| Verma et al., 2005 [ | 29/F | LASIK | — | PKP | Diagnosis after PKP |
| Ozbek et al., 2006 [ | 69/M | Trauma | Topical natamycin, amphoterin B → topical and oral voriconazole | ||
| Barnes et al., 2007 [ | 59/M | KPro | Topical amphotericin B | ||
| Bunya et al., 2007 [ | 69/M | Topical amphotericin B, natamycin → topical and oral voriconazole | |||
| Kocaturk et al., 2007 [ | 46/F | LASIK | Topical amphotericin B + natamycin + oral itraconazole | PKP | PKP after resolution of infection |
| Tu, 2009 [ | 39/M | SCL | Topical voriconazole → oral voriconazole + topical natamycin → intrastromal injection of voriconazole + topical caspofungin | ||
| Tu, 2009 [ | 45/M | Trauma | Topical natamycin + oral itraconazole → topical fluconazole | ||
| Tu, 2009 [ | 70/M | COAG | Topical fluconazole | ||
| Usui et al., 2009 [ | 55/M | Glaucoma | Topical fluconazole + miconazole → topical amphotericin B | ||
| Shen et al., 2010 [ | 62/F | Trauma | Topical natamycin + oral ketoconazole → intracameral voriconazole | Combined endophthalmitis | |
| Ursea et al., 2010 [ | 72/F | RGP lens | Topical natamycin and amphotericin B | PKP | |
| Yildiz et al., 2010 [ | 41/F | SCL | Topical natamycin → topical and oral voriconazole | ||
| Yildiz et al., 2010 [ | 26/F | SCL | Topical natamycin → topical voriconazole | ||
| Martone et al., 2011 [ | 68/M | Trauma | Topical + oral voriconazole | ||
| Neoh et al., 2011 [ | 67/M | Bullous keratopathy | Topical and intrastromal voriconazole + caspofungin | PKP | |
| Konidaris et al., 2013 [ | 66/F | PKP | Topical and oral voriconazole + topical amphotericin B | PKP |
M: male, F: female, HSV: herpes simplex virus, PKP: penetrating keratoplasty, ECCE: extracapsular cataract extraction, DM: diabetes mellitus, LASIK: laser-assisted in situ keratomileusis, Kpro: keratoprosthesis, SCL: soft contact lens, COAG: chronic open angle glaucoma, and RGP: rigid gas permeable lens.
Clinical features of Alternaria keratitis.
| Characteristics | Previous cases ( | Current cases ( |
|
|---|---|---|---|
| Age, median year (range) | 56 (26 to 72) | 62 (17 to 76) | 0.21 |
| Gender, number of males (%) | 17 (68%) | 4 (57%) | 0.32 |
| Risk factor, number (%) | |||
| Trauma | 9 (36%) | 5 (72%) | 0.06 |
| Preexisting corneal disease or surgery | 10 (40%) | 0 | <0.001 |
| Contact lens | 4 (16%) | 1 (14%) | 0.46 |
| Others | 1 (4%) | 1 (14%) | 0.26 |
| Corticosteroid use* | 14 (56%) | 0 | <0.001 |
| Medical treatment success with natamycin | 5 (33%) | 5 (83%) | 0.02 |
| Therapeutic surgery, number (%) | 8 (32%) | 1 (17%) | 0.16 |
*Only the patients with definite history of corticosteroid use were included.
†Topical natamycin +/− amphotericin B was used to treat 15 eyes among previous cases and 6 eyes in current series.